Skip to content

Study · Ex vivo tissue · mouse and rat · 2002

5 results

CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart.

Bodart V, Febbraio M, Demers A, McNicoll N, Pohankova P, Perreault A, Sejlitz T, Escher E, Silverstein RL, Lamontagne D, Ong H

Circulation research1 May 2002Cited by 114 (Europe PMC)

PMID11988484 (opens in a new tab)DOI10.1161/01.res.0000016164.02525.b4 (opens in a new tab)PepBankPUB-11988484
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabEx vivo tissueActivity measurement

    In perfused hearts, hexarelin increased coronary perfusion pressure in a dose-dependent manner, an effect linked to CD36 activation.

    In plain wordsIn perfused hearts, hexarelin raised the pressure needed to push fluid through heart vessels, and the rise grew with dose.

    Peptide
    Hexarelin
    Outcome
    IncreaseCoronary perfusion pressure in perfused hearts
    Study

    n: not reported in source

    perfused hearts
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Activation of CD36 in perfused hearts by hexarelin was shown to elicit an increase in coronary perfusion pressure in a dose-dependent manner.
  2. 02LabEx vivo tissueMechanism

    In perfused hearts from CD36-null mice, the hexarelin-induced rise in coronary perfusion pressure was lacking.

    In plain wordsIn mouse hearts lacking CD36, hexarelin did not raise coronary perfusion pressure.

    Peptide
    Hexarelin
    Outcome
    No significant changeCoronary response in CD36-null mouse hearts
    Study

    mousen: not reported in source

    perfused hearts from CD36-null mice
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    This effect was lacking in hearts from CD36-null mice and hearts from spontaneous hypertensive rats genetically deficient in CD36.
  3. 03LabEx vivo tissueMechanism

    In perfused hearts from spontaneously hypertensive rats genetically deficient in CD36, the hexarelin-induced rise in coronary perfusion pressure was lacking.

    In plain wordsIn rat hearts lacking CD36, hexarelin did not raise coronary perfusion pressure.

    Peptide
    Hexarelin
    Outcome
    No significant changeCoronary response in CD36-deficient spontaneously hypertensive rat hearts
    Study

    ratn: not reported in source

    perfused hearts from spontaneous hypertensive rats genetically deficient in CD36
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    This effect was lacking in hearts from CD36-null mice and hearts from spontaneous hypertensive rats genetically deficient in CD36.
  4. 04LabEx vivo tissueMechanism

    In perfused hearts, the coronary vasoconstrictive response to hexarelin correlated with CD36 expression and with covalent binding of hexarelin.

    In plain wordsIn perfused hearts, the vessel-narrowing response to hexarelin matched the amount of CD36 present.

    Peptide
    Hexarelin
    Outcome
    Not applicableCorrelation of coronary vasoconstriction with CD36 expression
    Study

    n: not reported in source

    perfused hearts
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The coronary vasoconstrictive response correlated with expression of CD36 as assessed by immunoblotting and covalent binding with hexarelin.

Studies that did not test the peptide alone1

In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Hexarelin.

  1. 05LabNot a test of Hexarelin aloneEx vivo tissueMechanism

    In rat cardiac membranes, a photoactivatable hexarelin derivative labeled a binding protein with N-terminal sequence identical to rat CD36.

    In plain wordsIn rat heart membranes, a labelled hexarelin probe attached to a protein that matched CD36.

    Peptide
    Hexarelin
    Outcome
    Not applicableHexarelin derivative binding protein in rat cardiac membranes
    Study

    ratn: not reported in source

    cardiac membranes
    Outcome group
    Receptor activity and mechanism · Cardiovascular

    Source sentences

    Summary
    To identify the molecular target mediating this activity, rat cardiac membranes were labeled with a radioactive photoactivatable derivative of hexarelin and purified using lectin affinity chromatography and preparative gel electrophoresis.
    2 context sentences
    Summary · context
    A binding protein of M(r) 84 000 was identified.
    Summary · context
    The N-terminal sequence determination of the deglycosylated protein was identical to rat CD36, a multifunctional glycoprotein, which was expressed in cardiomyocytes and microvascular endothelial cells.

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.